Publication|Articles|July 7, 2025
Supplements and Featured Publications
- Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Targeting Tear Evaporation: How Perfluorohexyloctane Ophthalmic Solution Redefines the Management of Evaporative Dry Eye Disease
Listen
0:00 / 0:00
Advertisement
This clinical brief is supported by Bausch + Lomb.
This AJMC® Clinical Brief provides a primer on dry eye disease (DED) diagnosis, pathophysiology, and treatment, highlights a DED treatment, and discusses real-world data about patient treatment satisfaction.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on AJMC
1
Real-World Data Show MASH Progresses Faster Than Trials Suggest
2
Adam Kittai, MD, on Sequencing, Cost, and the Road to CLL Cure
3
SYNC-T: Immunotherapy Platform Brings 4-Part Attack in Prostate Cancer, With More Trials Planned
4
Sarcoma's Rarity Limits Trials and Biomarker-Driven Treatment Options: Alexander Spira, MD, PhD, FACP, FASCO
5